Gulmez AO, Aydin S. Utility of cardiac bioenzymes in predicting cardiovascular outcomes in SARS-CoV-2. World J Virol 2023; 12(2): 132-135 [PMID: 37033145 DOI: 10.5501/wjv.v12.i2.132]
Corresponding Author of This Article
Ali Osman Gulmez, MD, Academic Research, Department of Radiology, Erzincan University, Mengucek Gazi Education and Research Hospital, Başbağlar Mahallesi Hacı Ali Akın Caddesi No. 32 Erzincan/Merkez, Erzincan 24100, Turkey. aliosmangulmez.2@gmail.com
Research Domain of This Article
Radiology, Nuclear Medicine & Medical Imaging
Article-Type of This Article
Letter to the Editor
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Virol. Mar 25, 2023; 12(2): 132-135 Published online Mar 25, 2023. doi: 10.5501/wjv.v12.i2.132
Utility of cardiac bioenzymes in predicting cardiovascular outcomes in SARS-CoV-2
Ali Osman Gulmez, Sonay Aydin
Ali Osman Gulmez, Department of Radiology, Erzincan University, Erzincan 24100, Turkey
Sonay Aydin, Department of Radiology, Erzincan University, Erzincan 24100, Turkey
Author contributions: Aydin S and Gulmez AO conceived the study; Aydin S and Gulmez AO were responsible for designing, materials and supervision; Aydin S and Gulmez AO did the literature search, wrote the manuscript, and reviewed the manuscript critically; All authors have read and approved the final manuscript.
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Ali Osman Gulmez, MD, Academic Research, Department of Radiology, Erzincan University, Mengucek Gazi Education and Research Hospital, Başbağlar Mahallesi Hacı Ali Akın Caddesi No. 32 Erzincan/Merkez, Erzincan 24100, Turkey. aliosmangulmez.2@gmail.com
Received: October 19, 2022 Peer-review started: October 19, 2022 First decision: November 22, 2022 Revised: November 30, 2022 Accepted: January 5, 2023 Article in press: January 5, 2023 Published online: March 25, 2023 Processing time: 153 Days and 3.4 Hours
Abstract
The relationship between coronavirus disease-19 (COVID-19) and cardiovascular diseases has been an important issue. Therefore, cardiac biomarkers and cardiac imaging have an important place in the diagnostic phase. It is important to know the relationship of biomarkers in COVID-19 so that we can understand the diagnosis of the disease, the predicted course and results after diagnosis.
Core Tip: Recommends biomarkers, especially troponin, in patients with Coronavirus disease-19-associated myocarditis and other myocardial damage; however, they have proven that in addition to traditional biomarkers, new cardiac bioenzymes such as prepesin, copeptin also increase and significantly worsen the prognosis. Knowing this, evaluation together with other imaging methods is also important in diagnosis.
